Sintilimab (Anti-PD-1)
Based on 3 publication(s) in Google Scholar
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Sintilimab (Anti-PD-1)
More
Biological Activity
Human IgG4 kappa
Human
Sintilimab (1 mg/kg, 3 mg/kg and 10 mg/kg, s.c., a single dose) demonstrates a high affinity for PD-1 molecules in NCI-H292 tumor-bearing NOG mice[2].
Sintilimab (20 mg/kg, i.p., once interval 2 days for 21 days) combined with prebiotics inhibits the volume of transplanted tumors in lung adenocarcinoma and alleviates the liver and kidney injury[4].
Pharmacokinetic parameters of Sintilimab (10 mg/kg, i.v., a single dose) in hPD-1 knock-in mouse[2]
| Parameter | AUC0-4 (h·μg/mL) | AUCinf (h·μg/mL) | CL (mL/h) | Cmax (μg/mL) | T1/2 (h) | Vss (mL) |
| Sintilimab | 6597.888 | 7846.554 | 0.025 | 218.519 | 35.623 | 1.262 |